contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-fluoguide-as-nasdaq-fluo-webcast-on-27-november-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

FluoGuide is a Danish company operating in the medical technology sector. The company's business focus is on research and development of treatments for various forms of cancer, with the greatest focus on the development of products that guide surgical procedures. The products bind to cancer cells, which then light up and are intended to be used to precisely remove harmful tumors in the patient's tissue.

FluoGuide

FluoGuide A/S will publish its Interim Report Q3 2025 on Thursday 27 November 2025.The following event will take place later that day:A live webcast for shareholders, analysts, investors and...

<div class="mfn-preamble"><p><strong>FluoGuide A/S will publish its Interim Report Q3 2025 on Thursday 27 November 2025.</strong></p></div><div class="mfn-body"><p><strong>The following event will take place later that day:</strong></p><p>A live webcast for shareholders, analysts, investors and representatives of the media:</p><p><strong>Topic: </strong>FluoGuide Operational and Financial Results for Q3 2025<br><strong>Date: </strong>Thursday 27 November 2025<br><strong>Time: </strong>14.00 CET</p><p>The webcast is hosted by analyst Christian Binder, Redeye. FluoGuide is represented by CEO Morten Albrechtsen and CFO Ole Larsen.</p><p>Please login to the webcast via the following link: <a rel="noopener" href="https://eur06.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.redeye.se%2Fevents%2F1127356%2Flive-q-fluoguide-2&amp;data=05%7C02%7Cole%40fluoguide.com%7C0c7d145925294c2b794e08ddf9d6749e%7C33e4848b585b4060ac70cf3efdbf4452%7C0%7C0%7C638941421702374139%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=3YktBzXW9FbC1TeVpPiNC4kgTp6GQRf4izjuLJf%2FTNM%3D&amp;reserved=0">https://www.redeye.se/events/1127356/live-q-fluoguide-2</a></p><p>Questions can be sent in advance by email to Christian Binder (<a rel="noopener" href="mailto:christian.binder@redeye.se">christian.binder@redeye.se</a>) or can be raised at the question session during the webcast.</p><p>A recorded version of the presentation will be available on the website after the webcast has concluded.</p></div><div class="mfn-footer mfn-contacts mfn-c60fb25dd154"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Morten Albrechtsen, CEO<br>FluoGuide A/S<br>Phone: +45 24 25 62 66<br>E-mail: ma@fluoguide.com</p></div><div class="mfn-footer mfn-67044b16f1f8"><p><strong class="mfn-heading-1">Follow FluoGuide on linkedIn</strong><br>Follow FluoGuide on LinkedIn: <a rel="noopener" href="https://www.linkedin.com/company/fluoguide/">https://www.linkedin.com/company/fluoguide/</a></p></div><div class="mfn-footer mfn-4fc4c77ad72e"><p><strong class="mfn-heading-1">Sign up to receive FluoGuide news</strong><br>Sign up to receive FluoGuide news: <a rel="noopener" href="https://fluoguide.com/investor/email-alerts/">https://fluoguide.com/investor/email-alerts/</a></p></div><div class="mfn-footer mfn-about mfn-889f859209e1"><p><strong class="mfn-heading-1">About FluoGuide</strong><br>FluoGuide lights up cancer to maximize surgical outcomes in oncology. FluoGuide’s lead product, FG001, is designed to improve surgical precision by lighting up cancer intraoperatively. The improved precision has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision enhances the likelihood of complete cure and lower healthcare costs. FluoGuide has demonstrated that FG001 is both effective and well tolerated several phase II clinical trials. The lead indications of FG001 are aggressive brain cancer (glioblastoma) and oral head and neck cancer. FluoGuide has entered partnerships with leading MedTech companies with the aim of accelerating development and commercialization. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.</p><p>For more information on FG001 or FluoGuide’s uPAR technology platform,  please visit our home page www.fluoguide.com</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/5f206966-fd90-4be8-a5c0-c30aa6476c43/invitation-to-fluoguide-a-s-nasdaq-fluo-webcast-on-27-november-2025.pdf" class="mfn-generated mfn-primary">Invitation to FluoGuide A/S (Nasdaq: FLUO) webcast on 27 November 2025</a></p></div>